Compare Ascendis Pharma A/S (ASND) vs Lucid Group Inc (LCID) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Lucid Group Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Lucid Group Inc trades at $5.55 (market cap $2.17B). The key difference: Ascendis Pharma A/S is far larger — about 8.2× Lucid Group Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Lucid Group Inc nearer its low. Which is the better fit depends on your goals.
| ASND | LCID | |
|---|---|---|
Market Cap | $17.74B | $2.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $31.30 |
52-Week Low | $163.32 | $4.70 |
Enterprise Value | $18.11B | $4.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Lucid Group (LCID) trades at $5.55, down 4.8% on the day, reflecting persistent bearish technical signals and fundamental challenges. The company continues to report significant losses, with a net income margin of -239.81% and negative cash flow from operations of $2.93B in 2025. Recent news highlights shareholder dilution concerns and multiple class-action lawsuits, adding to investor uncertainty.
The outlook remains highly speculative with substantial execution and liquidity risks, though a consensus analyst price target of $11.75 suggests potential upside if the company can achieve scale and improve profitability. High cash burn and competitive pressures in the EV market present significant headwinds for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →
